BiOrion Competitors and Similar CompaniesClear all

Sun Radiopharma's competitors and similar companies include HUYA Bioscience International, Ascendis Pharma and Replimune.
Sun Radiopharma
Sun Radiopharma
Sun Radiopharma is a manufacturer of human injectable pharmaceuticals.
HUYA Bioscience International
HUYA Bioscience International
HUYA Bioscience International is a company specializing in the biopharmaceutical products.
Ascendis Pharma
Ascendis Pharma
Ascendis Pharma is a biopharmaceutical company that specializes in endocrinology and oncology.
Replimune
Replimune
Replimune Ltd. develops oncolytic immunotherapies for the treatment of cancer.
Founding Date
Founding Date
1985
Founding Date
2004
Founding Date
2007
Founding Date
2015
Type
Type
Subsidiary
Type
Private
Type
Public
Type
Public
Tags
Locations
Locations
Billerica, US HQ
Locations
San Diego, US HQ
Chengdu Shi, CN
Guangzhou Shi, CN
Hangzhou, CN
Shenzhen Shi, CN
Shenzhen Shi, CN
Suzhou Shi, CN
see more
Locations
Hellerup, DK HQ
Heidelberg, DE
Palo Alto, US
Locations
Woburn, US HQ
Milton, GB
Woburn, US
Employees
Employees
46
Employees
1113% increase
Employees
1,017
Employees
10422% increase
Valuation ($)
Valuation ($)
N/A
Valuation ($)
N/A
Valuation ($)
7.7 b
Valuation ($)
823.3 m

Financial

Net income
Net income
N/A
Net income
N/A
Net income
(€228m) (FY, 2025)
Net income
($313.9m) (FY, 2026)

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
$ 12.6m
Total funding raised
$ 85.8m
Total funding raised
$ 30m
For sources of this data, please see the company profile

View Company Profiles

HUYA Bioscience International
HQ
San Diego, US
Employees
111↑ 3% increase

HUYA Bioscience International is a company specializing in the biopharmaceutical products.

View company
Ascendis Pharma
HQ
Hellerup, DK
Employees
1,017

Ascendis Pharma is a biopharmaceutical company that specializes in endocrinology and oncology.

View company
Replimune
HQ
Woburn, US
Employees
104↑ 22% increase

Replimune Ltd. develops oncolytic immunotherapies for the treatment of cancer.

View company